はい、労作時低酸素血症を伴う特発性肺線維症(IPF)患者に対する酸素療法は推奨されています。労作時低酸素血症は、運動中や労作中に血中の酸素レベルが異常に低下する状態を指します。この状態のIPF患者に酸素療法を行うことで、運動耐容能力が向上し、息切れの症状が軽減され、生活の質が改善される可能性があります (The BMJ)。
S MacIsaac, D Somboonviboon, C Scallan, M Kolb - Expert Opinion on Emerging …, 2024
… This review highlights the current landscape of IPF research in the development of novel compounds for the treatment IPF while also evaluating repurposed medications and their role in the management of IPF. The literature search includes …
… This article elaborates on the pathophysiology of IPF, its risk factors, and different advanced drug delivery systems for treating IPF. … IPF. This article comprehensively reviews different drugs and their novel delivery systems reported for treating …
Y Liang, Y Yan, N Liu, J Wang, C Fang - Journal of Ethnopharmacology, 2024
… to observe PANoptosis in bleomycin-induced IPF and to assess the efficacy and mechanism of action of SXD in the treatment of IPF. … In this study, bleomycin was used to induce idiopathicfibrosis in rats to observe whether PANoptosis occurs …
Q Guan, Z Zhang, P Zhao, L Huang, R Lu, C Liu… - International …, 2024
… , and identified individualized DEGs and the common DEGs for IPF. Through the protein–protein interaction (PPI) network analysis and RNA-seq data of mice with pulmonaryfibrosis(PF) measured by our laboratory, IPF hub genes were identified …
Y Moodley - American Journal of Respiratory and Critical Care …, 2024
… may be (mis)-classified as IPF. This scenario can lead the MDD to reclassify IPF to a fibrosing CTD-ILD when the full clinical and serology picture unveils itself. Furthermore, proteomic comparisons between fibrosing CTD-ILD and IPFmight also …
Q Zeng, B Wen, X Liu, Y Luo, Z Hu, L Huang, X Zhang… - Chinese Medicine, 2024
… Idiopathicpulmonaryfibrosis is a persistent disease of the lung interstitium for which there is no efficacious pharmacological therapy. … in pulmonaryfibrosis is yet to be established. Hence, in this investigation, it was attempted to figure out the anti-pulmonary …
… idiopathicpulmonaryfibrosis (IPF), and retinitis pigmentosa (RP,) (ii), inflammation-based pathologies and (iii) cancer. To identify new pharmacological tools against IPF, … THIQ and spiro-THIQ analogues were revealed effective in attenuating IPF-related …
… The drug pirfenidone has shown several anti-fibrotic effects in animal models of heart diseases and is already approved for the treatment of idiopathicpulmonaryfibrosis. This led to the hypothesis that pirfenidone could have beneficial effects as …
AA Alamer, C Ward, I Forrest, M Drinnan, J Patterson - BMJ Open, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a chronic and progressive interstitial lung disease characterised by unknown causes. It is primarily … Typical symptoms of IPF include chronic exertional dyspnoea and a persistent dry cough.2 Risk factors for …
X He, J Ji, Z Pei, Z Luo, S Fang, X Liu, Y Lei, H Yan… - Annals of Medicine, 2024
… Anxiety and depression are common comorbidities in idiopathicpulmonaryfibrosis(IPF) that impair health-related quality of life. However, there is a lack of studies focusing on the mental disorder of IPF after antifibrotic treatment and their …
AM Shahzad, W Lu, S Dey, P Bhattarai, AV Gaikwad… - Journal of Clinical Medicine, 2024
… Background: Idiopathicpulmonaryfibrosis(IPF) is an irreversible lung fibrotic disorder of … Methods: Immunohistochemical staining was carried out for lung resections from IPF patients (n … and alveolar macrophages was higher in IPF than …
… on IPF and may serve as a potential therapeutic target for IPF, providing inspiration and guidance for the diagnosis and treatment of IPF. … cathepsin H reduces the risk of developing IPF and may serve as a potential therapeutic target …
S Kansakar, S Shikhrakar, A Basnet, S Gautam… - Journal of the American …, 2024
… IdiopathicPulmonaryFibrosis (IPF), share common risk factors and pathophysiological pathways with acute myocardial infarction (AMI). However, there is a scarcity of data regarding the influence of IPF … diagnosis of AMI with and …
JH Lin, CC Liu, CY Liu, TW Hsu, YC Yeh, CK How… - Redox Biology, 2024
… The aetiologies of ILD include smoking, hypersensitivity, and chronic viral infections, and most cases are idiopathic. Idiopathicpulmonaryfibrosis (IPF) is considered the most important and severe subtype of ILD because its morbidity and …
J Zhu, Q Jiang, S Gao, Q Xia, H Zhang, B Liu, R Zhao… - Pharmacological Research, 2024
… IPF, we examined the expression of IL20, the ligand of IL20Rb, in the serum of IPF patients, and as expected, IL20 was highly expressed in the serum of IPF … silencing IL20Rb in macrophages may be a potential clinical strategy for the …
B Liu, Q Jiang, R Chen, H Zhang, Q Xia, C Shao, X Liu… - International …, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a heterogeneous group of lung diseases with different etiologies and characterized by progressive fibrosis. This disease usually causes pulmonary structural remodeling and decreased pulmonary function …
… Fibrotic diseases (such as idiopathicpulmonaryfibrosis (IPF) and chronic kidney disease), which are usually associated with old age, are … leverages a multistage generative artificial intelligence (AI) platform to identify and validate a small-molecule …
… IdiopathicPulmonaryFibrosis (IPF) is a chronic disease with an unknown etiology and lacks speci c treatment. Macrophages, as a major … 8 IPF patients, we revealed distinct macrophage subtypes in IPF lung tissue. In this study, we identi ed a …
R Yamazaki, O Nishiyama, K Yosikawa, K Gose… - Respiratory Investigation, 2024
… with idiopathicpulmonaryfibrosis [IPF] and 39 with non-IPF fIIP) who were hospitalized a total of 155 times (111 with IPF and 44 with non-IPF … Idiopathicpulmonaryfibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) of …
F Luppi, G Ferrara - American Journal of Respiratory and Critical Care …, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a rare and devastating disease causing irreversible … able to show any efficacy of the new drugs for IPF over the control groups. All the recent RCTs … Although the clinical need is important, since at least …
「強力な炎は小さな火花に続くことがある」:これは特発性肺線維症における C-Jun N 末端キナーゼ 1 (JNK) 阻害剤の場合ですか?
S Vang, ES Helton, Y Guo, B Burpee, E Rose, M Easter… - Frontiers in Immunology
… Background Idiopathicpulmonaryfibrosis(IPF) is a chronic pulmonary disease that is 24 characterized by an excessive accumulation of extracellular matrix (ECM) proteins (ie collagens) 25 in the parenchyma, which ultimately leads to respiratory …
A Adegunsoye, JA Kropski, J Behr, TS Blackwell… - American Journal of …, 2024
… into the risk factors for and mechanisms that mediate idiopathicpulmonaryfibrosis (IPF) … five novel loci associated with idiopathicpulmonaryfibrosis. Thorax 2022; 77: 829-833. … Idiopathicpulmonaryfibrosis: a composite physiologic index …
YM Mari, MP Fraix, DK Agrawal - Archives of internal medicine research, 2024
… Idiopathicpulmonaryfibrosis (IPF) constitutes a long-term disease with a complex pathophysiology composed of multiple molecular actors … One of the risk factors for the development of IPF is the pre-existing condition of diabetes mellitus. Both, IPF …
M Hanibuchi, H Ogino, S Sato, Y Nishioka - The Journal of Medical Investigation, 2024
… Idiopathicpulmonaryfibrosis (IPF) is one of the most common ILDs. The incidence of LC comorbidity with IPF is generally considered to be approximately 10-20% (2). The greatest concern in LC-ILD is acute exacerbation (AE) of ILD (AE-ILD) …
K Yu, W Li, W Long, Y Li, Y Li, H Liao, J Liu - 2024
… Interstitial lung disease (ILD) has exhibited limited overall treatment advancements, with scant exploration into circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathicpulmonaryfibrosis(IPF). Therefore …
A Sonaglioni, A Caminati, E Grasso, M Colleoni… - The International Journal of …, 2024
… idiopathicpulmonaryfibrosis (IPF) patients without severe pulmonary hypertension and at assessing its correlation with effective arterial elastance index (EaI). METHODS: Multi-instrumental data obtained in 60 IPF … was significantly lower in …
SL Tansley, F McMorrow, CV Cotton, H Adamali… - Clinical Immunology, 2024
… Randomly selected serum samples from three patient subtypes of ILD (as diagnosed by their local respiratory medicine teams) were analysed: 251 patients with of idiopathicpulmonaryfibrosis (IPF), 206 with idiopathic non-specific interstitial …
K Akata, K Yamasaki, T Kawaguchi, Y Chiba, K Sennari… - Heart & Lung, 2024
… with acute exacerbation of idiopathicpulmonaryfibrosis (AE-IPF), specifically, the interactions between respiratory pathogens and AE-IPF during the … Idiopathicpulmonaryfibrosis (IPF) is a progressive fibrotic lung disease of unknown etiology. It …
J Park, CH Lee, K Han, SM Choi - Scientific reports, 2024
… A case-control study was performed to evaluate the association between statin use and the risk for IPF, and the multivariable analysis revealed that statin use was associated with a lower risk for IPF (adjusted OR 0.847, 95% CI 0.800-0.898). Using …
S Vang, Y Livelo, B Burpee, MJ Hirsch, EL Matthews… - Journal of Clinical and …, 2024
… Lastly, a mouse model of bleomycin-induced pulmonaryfibrosis was examined following … -GlcNAc staining was increased in IPF lung tissue compared to non-IPF control lungs. In primary … in pulmonaryfibrosis, and we show that O-GlcNAc is …
N Wada, KS Lee, H Hatabu - Current Pulmonology Reports, 2024
… In a series of studies, ILA and pulmonaryfibrosis, especially idiopathicpulmonaryfibrosis (IPF), have been shown to potentially share common clinical, biological, physiological, radiological, and histopathological features, and thus they have …
R Wan, S Long, S Ma, P Yan, Z Li, K Xu, H Lian, W Li… - Respiratory Research, 2024
… IPF lung tissues and control non-IPF lung tissue samples were recruited based on the ATS/ERS/JRS/ALAT Clinical Practice Guidelines at Henan Provincial Chest Hospital. The study was approved by the Henan Provincial Chest Hospital Medical …
C Jia, M Yang, G Xiao, Z Zeng, L Li, Y Li, J Jiang, A Xu… - Phytomedicine, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a persistent and advanced pulmonary ailment. The roles of innate immunity and adaptive immunity … potential mechanism underlying the anti-IPFeffect of ESL. BLM-induced IPF mice were used to validate …
M Patel, Y Post, N Hill, A Sura, J Ye, T Fisher, N Suen… - Respiratory Research, 2024
… Idiopathicpulmonaryfibrosis (IPF) is an interstitial lung disease characterized by areas of myofibroblast accumulation and extracellular matrix (ECM) deposition, disruption of alveolar architecture, and restricted lung physiology [1,2,3]. The median …
HY Wang, SC Tsai, YC Lin, JU Hou, CH Chao - BMC Pulmonary Medicine, 2024
… Novel antifibrotic agents such as nintedanib and pirfenidone have demonstrated effectiveness in managing patients with idiopathicpulmonaryfibrosis (IPF). Nintedanib functions as an intracellular inhibitor targeting vascular endothelial …
参考文献 Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011. Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005.